Real‐world practice of Helicobacter pylori management: A survey among physicians in Southeast Asia
Authors:
- Duc Trong QuachDQDuc Trong Quach
- Ratha‐Korn VilaichoneRVRatha‐Korn Vilaichone
- Mai Ngoc LuuMLMai Ngoc Luu
- Yeong Yeh LeeYLYeong Yeh Lee
- Tiing Leong AngTATiing Leong Ang
- Muhammad MiftahussururMuhammad Miftahussurur
- Than Than AyeTAThan Than Aye
- Dewi Norwani BasirDBDewi Norwani Basir
- Varocha MahachaiVMVarocha Mahachai
- 27 August 2023
- journal article
- research article
- Published by Wiley in Helicobacter
- Vol. 28 (6) , e13018
Abstract
Background: Multidrug‐resistant Helicobacter pylori strains are emerging in Southeast Asia. This study evaluates the region's real‐world practice in H. pylori management.Materials and Methods: Physicians who managed H. pylori eradication in daily practice across 10 Southeast Asian countries were invited to participate in an online questionnaire, which included questions about the local availability of antimicrobial susceptibility tests (ASTs) and their preferred eradication regimens in real‐world practice. An empiric regimen was considered inappropriate if it did not follow the local guidelines/consensus, particularly if it contained antibiotics with a high reported resistance rate or was recommended not to be empirically used worldwide.Results: There were 564 valid responses, including 314 (55.7%) from gastroenterologists (GIs) and 250 (44.3%) from non‐GI physicians. ASTs were unavailable in 41.7%. In countries with low and intermediate clarithromycin resistance, the most common first‐line regimen was PAC (proton pump inhibitor [PPI], amoxicillin, clarithromycin) (72.7% and 73.2%, respectively). Regarding second‐line therapy, the most common regimen was bismuth‐based quadruple therapy, PBMT (PPI, bismuth, metronidazole, tetracycline) (50.0% and 59.8%, respectively), if other regimens were used as first‐line treatment. Concomitant therapy (PPI, amoxicillin, clarithromycin, metronidazole) (30.5% and 25.9%, respectively) and PAL (PPI, amoxicillin, levofloxacin) (22.7% and 27.7%, respectively) were favored if PBMT had been used as first‐line treatment. In countries with high clarithromycin resistance, the most common first‐line regimen was PBMT, but the utilization rate was only 57.7%. Alarmingly, PAC was prescribed in 27.8% of patients, ranking as the second most common regimen, and its prescription rate was higher in non‐GI physicians than GI physicians (40.1% vs. 16.2%, p < 0.001).Conclusions: Choosing inappropriate regimens containing antibiotics with high resistance rates is not uncommon in Southeast Asia, especially among non‐GI physicians. In countries with high clarithromycin resistance, the PBMT regimen is underutilized.Keywords
This publication has 26 references indexed in Scilit:
- Helicobacter pylori management in ASEAN: The Bangkok consensus reportJournal of Gastroenterology and Hepatology, 2017
- Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-AnalysisGastroenterology, 2017
- Real‐world practice and Expectation of Asia‐Pacific physicians and patients in Helicobacter Pylori eradication (REAP‐HP Survey)Helicobacter, 2017
- ACG Clinical Guideline: Treatment of Helicobacter pylori InfectionAmerican Journal of Gastroenterology, 2017
- Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus ReportGut, 2016
- The Toronto Consensus for the Treatment of Helicobacter pylori Infection in AdultsGastroenterology, 2016
- Role of bismuth in improving Helicobacter pylori eradication with triple therapyGut, 2016
- Review article: the global emergence ofHelicobacter pyloriantibiotic resistanceAlimentary Pharmacology & Therapeutics, 2015
- Kyoto global consensus report onHelicobacter pylorigastritisGut, 2015
- High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in VietnamInternational Journal of Antimicrobial Agents, 2015